4 results
Approved WMOCompleted
Primary Objective:To evaluate if treatment with RVX000222 as compared to placebo increases time to thefirst occurrence of narrowly defined MACE. Narrowly defined MACE is defined as a singlecomposite endpoint of CV death or non-fatal MI or stroke.…
Approved WMOCompleted
What is the prevalence of gastro-intestinal disorders and which are the determinants?
Approved WMOCompleted
Please refer to protocol, section 1.2 "Rationale"
Approved WMOCompleted
Primary ObjectiveTo evaluate the effect of RVX000222 on the change in burden of coronary atherosclerosis, as measured by percent atheroma volume (PAV), in patients with coronary artery disease and a low level of HDL-C requiring angiography for a…